"Dr Jon Bruss strengthens the Medpace position supporting our sponsors who are advancing new drugs for infectious disease and vaccines, one of the largest pharmaceutical pipelines for development by biopharmaceutical sponsors," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "Dr. Bruss’s experience and industry knowledge will allow us to provide strategic consultation to our sponsors in designing innovative clinical trial methods for many of our customers engaged in bringing new drugs to market in this challenging therapeutic area."
Dr Jon Bruss has spent 20 years in drug development with global, clinical and regulatory expertise, managing clinical trials in the area of infectious diseases, including leading drug development in the US, Europe, and Asia. His clinical development experience includes the first in novel classes of compounds, involving adults, the elderly, children, and neonates. Dr. Bruss has held positions of increasing responsibility, including Chief Medical Officer, in both large and small pharmaceutical companies. He has also served as a consultant to numerous small biotechnology and large pharmaceutical companies. In addition, his clinical and academic research experience has included infectious disease research, vaccine research, public health management and tuberculosis control.
Dr Bruss received his Doctor of Medicine degree from the University of New Mexico, School of Medicine and his undergraduate degree in Biology from the University of Utah. He completed his Internship and Residency in pediatrics at the Children’s Hospital of New Mexico and Clinical and Research Fellowships in Infectious Diseases at Harvard Medical School. In addition, he earned a Master of Business Administration at Northwestern University – Kellogg School of Management and a Master of Science in Public Health from Tulane University.